<DOC>
	<DOCNO>NCT00237146</DOCNO>
	<brief_summary>An open , multicenter prospective study evaluate impact treatment zoledronic acid 4 mg , quality life skeletal-related event patient prostate cancer bone metastasis respond hormonal therapy . Zoledronic acid give patient 15 minute-infusion every 4 week skeletal-related event occurs .</brief_summary>
	<brief_title>Study Evaluate Zoledronic Acid Quality Life Skeletal-related Events Adjuvant Treatment Patients With Hormone-naïve Prostate Cancer Bone Metastasis Who Have Undergone Orchiectomy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Age ≥18 histologically confirm adenocarcinoma prostate . Orchidectomy within four previous week enter study . bone metastasis evidence bone scan . A hip DEXA study DS &lt; 3 . No hormonal therapy previous enter study . ECOG performance score 02 . Signed write informed consent . Abnormal renal function evidence creatinine clearance ≤60 ml/min . Any kind hormonal therapy prostate cancer previous enter study . Serum calcium correct albumin level &lt; 8.0 mg/dl . WBC &lt; 3.0x10^3 , ANC &lt; 1500/mm3 , Hemoglobin &lt; 8.0 g/dl , platelet &lt; 75 x 10^3/l . Abnormal hepatic function evidence ALT AST value &gt; 2.5 UNL Subjects malignant disease affect bone . Subjects non malignant disease jeopardize evaluation primary objective trial ( severe osteoporosis ) aloud perform trial evaluation . Known hypersensibility zoledronic acid bisphosphonates . Subjects investigator 's opinion cooperate protocol . Other protocol inclusion/exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Zoledronic acid</keyword>
	<keyword>Bone metastasis</keyword>
</DOC>